PERSONALIZED CELL THERAPY MARKET ANALYSIS

Personalized Cell Therapy Market Size and Trends

Global personalized cell therapy market is estimated to be valued at USD 14.12 Bn in 2024 and is expected to reach USD 65.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 24.4% from 2024 to 2031.

To learn more about this report, request sample copy

Advancements in cell and gene therapy coupled with increasing investment by key players can drive the market growth. Global personalized cell therapy market is expected to witness significant growth over the forecast period due to factors  such as rising prevalence of cancers and genetic disorders, increasing demand for targeted therapies and development of novel advanced therapies. Improvements in healthcare systems worldwide can also drive the market growth.

Rising Prevalence of Cancer

Rising prevalence of cancer around the world can drive the global personalized cell therapy market growth. This increase in cancer incidence has boosted investments in developing advanced treatment methods like personalized cell therapy. In personalized cell therapy, a patient’s own immune cells are engineered to target the specific cancer type and mutation. These living drugs are then infused back into the patient to fight the cancer in a personalized way. Compared to traditional chemotherapy, targeted cell therapies have shown promising results with fewer side effects. Many such therapies have recently received regulatory approvals to treat various blood cancers like lymphoma and leukemia. Researchers are also working on customizing these living cell therapies for solid tumors like lung cancer, breast cancer, and others. Growing success and efficacy of cell therapies in clinical trials and first approvals have boosted confidence among the medical community, patients as well as investors. Biotech and pharmaceutical companies are now dedicating more resources to develop the next generation of personalized cell therapies at a larger scale.

For instance, according to the data published by World Health Organization in February 2024, according to data by The International Agency for Research on Cancer (IARC), ahead of World Cancer Day, released new estimates showing a significant global burden of cancer in 2022. There were approximately 20 million new cases and 9.7 million deaths from cancer worldwide. The data highlights disparities, with underserved populations facing a disproportionate impact. Lung, breast, and colorectal cancers were the most common types globally, with lung cancer leading in both new cases and deaths. Inequities in cancer care financing were also evident, with many countries not adequately covering essential cancer and palliative care services as part of universal health coverage.

Advancements in cell therapy research

Advancements in cell therapy research can transform medicine and treat previously incurable diseases. Scientists are making progress in developing customized treatments that use a patient's own cells to fight various life-threatening illnesses. This pioneering work in personalized cell therapies can drive the market growth. Researchers have had some early successes using cells from bone marrow, blood and skin to treat cancers like leukemia and lymphomas. For example, stem cell therapies are being tested for conditions like heart disease, diabetes, Parkinson's and Alzheimer's with hope that damaged or dead cells can be replaced. The pandemic has also accelerated vaccine research using cell culture technology paving way for new strategies against various viruses.

As the science advances, more cell therapy clinical trials are planned for a wider range of health issues. According to World Health Organization, 500 trials studying over 25,000 patients was conducted by 2023 across key markets of U.S., Europe, China, and India. The data demonstrates growing interest from pharmaceutical companies and research organisations to develop these next-generation treatment options. As trials show success, regulatory approvals will increase bringing novel therapies to patients faster and increasing investments in this sector.